In November 2025, the Indian government unveiled an ambitious vision: the Rs 1 lakh crore Research, Development, and Innovation (RDI) fund. Prime Minister Narendra Modi championed the initiative as a transformative vehicle designed to provide "patient capital" to sectors that private venture capital firms traditionally shy away from—areas defined by high risk and long gestation periods, such as deep-tech, drone-defense systems, satellite technology, and DNA-based data storage.
Nearly a year later, however, the narrative surrounding the fund has shifted from high-octane optimism to institutional stagnation. Rather than acting as a catalyst for the startup ecosystem, the RDI fund has become a symbol of bureaucratic friction. According to industry insiders—including managing partners at venture capital firms overseeing billions in assets—the fund is not accelerating innovation; it is actively slowing it down.
The Promise vs. The Reality: A Chronology of Delays
The Anusandhan National Research Foundation (ANRF), the body tasked with housing and overseeing the RDI fund, was intended to be the engine of this innovation drive. In May 2026, the rhetoric from the top was nothing short of urgent. Shivkumar Kalyanaraman, CEO of the ANRF, promised that the first cheques for approved Alternative Investment Funds (AIFs) would be dispatched "in the coming days." The objective was to operate with "record speed."
The reality on the ground has been starkly different.
- January 2026: Fund managers began submitting their applications for RDI capital, expecting a streamlined, tech-enabled evaluation process.
- April 2026: Many firms, proactive in their approach, began issuing requests for proposals (RFPs) and shortlisting startups, anticipating that the promised government liquidity was imminent.
- August 2026: By the first week of August, the process had hit a wall. Over 20 fund managers were still listed as "due to be appointed," and many firms that had already begun the groundwork found themselves in a state of limbo.
For a venture capital ecosystem that thrives on momentum, the delay has been costly. "We submitted our application in January," says one Bengaluru-based fund manager. "But now, the entire funding cycle is delayed by almost a year. We are effectively stuck because we now have to go back and renegotiate with our private Limited Partners (LPs) after the RDI fund approval, which is a massive administrative and credibility hurdle."
Fiscal Contraction: Where Did the Money Go?
The most jarring aspect of the RDI fund’s performance lies in its fiscal management. While the headline figure of Rs 1 lakh crore generated significant media buzz, the actual budgetary allocation for the fiscal year 2026 (FY26) was significantly curtailed.
According to government data, the initial budgetary allocation was slashed to Rs 3,000 crore. Of that amount, the actual disbursement has been even more conservative. The ANRF has only disbursed Rs 500 crore to the Technology Development Board (TDB). While the TDB has managed to commit Rs 2,192 crore to 22 startups, the gap between committed capital and actual, liquid funds remains a point of contention for startups that need runway to survive.
Furthermore, the Biotechnology Industry Research Assistance Council (BIRAC)—a public-sector entity—has committed Rs 390 crore to eight startups. Yet, in a glaring example of administrative misalignment, BIRAC has reportedly not received any funds from the ANRF to back these commitments. This leaves the startups in a precarious position: they have a government "commitment," but no cash in the bank to begin their research.
The "Patient Capital" Paradox
The primary mandate of the RDI fund was to provide "patient capital"—long-term investment for technologies that do not fit the typical 5–7 year exit horizon of traditional VC. This is vital for India’s ambition to become a global leader in high-tech manufacturing and defense.
However, the "patient" nature of the capital has inadvertently become an excuse for lethargy. Investors argue that the lack of clear, transparent, and time-bound disbursement protocols is forcing them to reconsider their participation. When a VC firm manages a corpus of over $1 billion, they are accustomed to a degree of professional rigor that the current RDI framework is failing to meet.
"When you ask a private firm to partner with a public fund, there is an expectation of a collaborative effort," says the managing partner of a top-tier VC firm. "Instead, we are finding that the bureaucratic layers are so thick that the cost of capital—not in terms of interest, but in terms of time and opportunity—is becoming prohibitive."
Implications for the Startup Ecosystem
The failure to deploy capital efficiently has three primary negative implications for the Indian startup ecosystem:
1. Erosion of Investor Confidence
Institutional investors, both domestic and international, rely on the stability of government policy. When a flagship program like the RDI fund fails to meet its own deadlines, it sends a signal of systemic instability. This uncertainty makes it difficult for fund managers to raise follow-on capital from private LPs.
2. Talent Attrition and Brain Drain
The sectors targeted by the RDI fund—satellite tech, drones, and advanced biology—require highly specialized talent. These professionals are in high demand globally. If startups cannot pay salaries or fund equipment purchases because the RDI funding is stuck in a bureaucratic loop, the best talent will inevitably migrate to markets with more reliable funding environments, such as the US, Singapore, or the EU.
3. Stunted Technological Sovereignty
India’s push for "Atmanirbhar Bharat" (self-reliance) in critical technologies like defense and data storage relies on the success of these startups. By slowing down the funding, the government is essentially delaying its own strategic goals. In deep-tech, speed is not just a business metric; it is a competitive advantage. If Indian startups fall behind their global peers by a year, it may take them a decade to catch up.
Official Responses and the Road Ahead
To date, the official response from the ANRF and associated bodies has been sparse. Communication with fund managers remains intermittent, and there is little transparency regarding why the disbursement of funds is being delayed.
For the startup founders who were promised a new dawn of government-backed research funding, the silence is deafening. Industry bodies are now calling for a "reset" of the RDI fund’s operational structure. Suggestions include:
- Establishing a Single-Window Disbursement Platform: Reducing the number of intermediaries (like the TDB and BIRAC) that sit between the ANRF and the startups.
- Mandatory Timelines: Implementing a "guillotine clause" where funding applications must be approved or rejected within a fixed 90-day window.
- Independent Oversight: Including private sector representatives in the decision-making committees to ensure that the process remains grounded in commercial reality rather than purely bureaucratic procedure.
Conclusion
The RDI fund was born out of a realization that India’s R&D output, relative to its economic size, has historically been abysmal. The intention to rectify this through state-backed patient capital was, and remains, a sound economic strategy. However, the implementation has been plagued by a disconnect between policy ambition and administrative execution.
As the fiscal year progresses, the government faces a critical choice: either it must overhaul the RDI fund’s management to ensure capital flows at the speed of modern business, or it risks cementing the fund as a cautionary tale of how bureaucracy can derail innovation. For the startups currently waiting for their first cheques, the clock is ticking—and they simply do not have the luxury of waiting another year.
